| Number |
Title |
Publication
|
| GOG-0248 |
Phase II Randomized Study of Temsirolimus With or Without Hormonal Therapy Comprising Megestrol Acetate and Tamoxifen Citrate in Patients With Advanced, Persistent, or Recurrent Endometrial Carcinoma |
|
| GOG-0229I |
Phase II Study of Brivanib Alaninate in Patients With Recurrent or Persistent Endometrial Carcinoma |
|
| GOG-0229G |
Phase II Study of Bevacizumab and Temsirolimus in Patients With Recurrent or Persistent Endometrial Carcinoma |
|
| GOG-0229F |
Phase II Study of VEGF Trap in Patients With Recurrent or Persistent Endometrial Carcinoma |
|
| GOG-0229E |
Phase II Study of Bevacizumab in Patients With Recurrent or Persistent Endometrial Cancer |
|
| GOG-0229D |
Phase II Study of Lapatinib in Patients With Recurrent or Persistent Endometrial Carcinoma |
|
| GOG-0229C |
Phase II Study of Gefitinib in Patients With Persistent or Recurrent Endometrial Carcinoma |
|
| GOG-0229B |
Phase II Study of Thalidomide in Patients With Recurrent or Persistent Endometrial Cancer |
PMID 17306350
|
| GOG-0224 |
Phase II Randomized Study of Megestrol Acetate in Patients With Endometrial Intraepithelial Neoplasia or Atypical Endometrial Hyperplasia |
|
| GOG-0211 |
Phase II Pilot Study of Medroxyprogesterone in Patients With Endometrioid Adenocarcinoma of the Uterine Corpus |
|
| GOG-0209 |
Phase III Randomized Study of Doxorubicin, Cisplatin, Paclitaxel, and Filgrastim (G-CSF) Versus Carboplatin and Paclitaxel in Patients With Stage III or IV or Recurrent Endometrial Cancer |
|
| GOG-0189 |
Phase III Randomized Study of Doxorubicin, Cisplatin, Paclitaxel, and Filgrastim (G-CSF) Versus Tamoxifen and Megestrol in Patients With Stage III or IV or Recurrent Endometrial Cancer |
|
| GOG-0188 |
Phase II Study of Fulvestrant in Patients With Newly Recurrent, Persistent, or Metastatic Endometrial Cancer |
|
| GOG-0184 |
Phase III Randomized Adjuvant Study of Tumor Volume-Directed Pelvic Radiotherapy With or Without Paraaortic Radiotherapy Followed By Cisplatin and Doxorubicin With or Without Paclitaxel in Patients With Stage III Endometrial Carcinoma |
|
| GOG-0181B |
Phase II Study of Trastuzumab (Herceptin®) in Patients With Advanced, Recurrent, or Persistent Endometrial Adenocarcinoma |
PMID 1984088
|
| GOG-0177 |
Phase III Randomized Study of Doxorubicin/Cisplatin With or Without Paclitaxel and Filgrastim (G-CSF) Support in Patients with Stage III, Stage IV, or Recurrent Endometrial Cancer |
|
| GOG-0163 |
Phase III Randomized Study of Doxorubicin/Cisplatin vs Doxorubicin/Paclitaxel/G-CSF for Primary Stage III/IV or Recurrent Endometrial Carcinoma |
|
| GOG-0156 |
Phase III Randomized Study of Adjuvant Pelvic Irradiation vs DOX/CDDP for Stage IB/IC/IIA/IIB Endometrial Carcinoma |
Terminated
|
| GOG-0137A |
Phase III Randomized Study of Estrogen Replacement Therapy Versus Placebo in Women With Stage I or II Endometrial Adenocarcinoma |
|
| GOG-0129Q] |
Phase II Study of Gemcitabine Hydrochloride in Patients With Recurrent or Persistent Endometrial Adenocarcinoma |
|
| GOG-0129P |
Phase II Study of Ixabepilone in Patients With Recurrent or Persistent Endometrial Adenocarcinoma |
PMID 19451430
|
| GOG-0129O |
Phase II Study of Pemetrexed Disodium in Patients With Persistent or Recurrent Endometrial Adenocarcinoma |
PMID 19804902
|
| GOG-0129N |
Phase II Study of Docetaxel in Patients With Recurrent or Persistent Endometrial Carcinoma |
PMID 18675446
|
| GOG-0129M |
Phase II Study of Flavopiridol in Patients With Recurrent or Persistent Endometrial Carcinoma |
PMID 15978659
|
| GOG-0129K |
Phase II Study of Oxaliplatin in Patients With Persistent or Recurrent Endometrial Carcinoma |
PMID 16712905
|
| GOG-0087J |
Phase II Study of Doxorubicin HCl Liposome in Patients With Recurrent or Advanced Uterine Sarcoma |
PMID 15721421
|
| GOG-0086M |
Phase II Study of Doxorubicin HCl Liposome in Patients With Advanced or Recurrent Endometrial Cancer |
PMID 15975638
|
| GOG-0026A |
Master Protocol Template for Individual Phase II Studies of New Drug Therapies in Patients With Metastatic or Recurrent Gynecologic Malignancies |
|
| GOG-9908 |
Phase I Study of Doxorubicin and Cisplatin Followed By Whole Abdominal Radiotherapy in Patients With Stage III or IV Endometrial Cancer |
PMID 19135232
|
| GOG-9907 |
Phase I Study of Paclitaxel and Cisplatin With Radiotherapy in Patients With Stage III or IV Endometrial Cancer |
PMID 18962846
|
| GOG-9905 |
Phase III Randomized Study of Adjuvant Radiotherapy With or Without Cisplatin and Paclitaxel After Total Abdominal Hysterectomy and Bilateral Salpingo-oophorectomy in Patients With Stage I or II Endometrial Cancer (also RTOG 9905) |
Terminated
|
| GOG-9902 |
Quality of Life of Gynecologic Cancer Survivors |
|
| GOG-9805 |
Phase II Study of Amifostine for Protection Against Cisplatin and Paclitaxel Induced Neurotoxicity in Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer |
PMID 14615449
|
| GOG-9405 |
Phase I Study of Paclitaxel Combined with Fixed Doses of CDDP/DOX for Advanced Gynecologic Malignancies and Recurrent Bladder Cancer with or without Pelvic Irradiation |
PMID 11181665
|
| GOG-9403 |
Phase I Dose-Seeking Study of TAX Administered During Pelvic Irradiation for Advanced or Recurrent Cancer of the Cervix, Vagina, Endometrium, or Bladder |
|
| GOG-9301 |
Phase I Study of Weekly CDDP and Whole-Abdominal Radiotherapy Followed by DOX/CDDP in Patients with Stage III/IV Endometrial Carcinoma |
PMID 15385116
|
| GOG-9206 |
Phase II Study of Laparoscopic-Assisted Vaginal Hysterectomy/Bilateral Salpingo-Oophorectomy, Intraperitoneal Staging, and Pelvic and Aortic Lymph Node Sampling in Patients with Presumed Stage I/IIA Adenocarcinoma of the Endometrium |
PMID 15086735
|
| GOG-9102 |
The Effect of Alopecia on the Cancer Patient's Body Image and the Role of Audiovisual Information on Improving Body Image |
|
| GOG-9101 |
Phase I Study of Intraperitoneal TAX in Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma |
PMID 8523061
|
| GOG-9001 |
Phase I Limited-Access Study of Weekly Cisplatin and Whole-Abdominal Irradiation in Patients with Stage III/IV Endometrial Carcinoma |
PMID 8946862
|
| GOG-8909 |
Phase I Study of CDDP plus Cyclosporine in Patients with Refractory Gynecologic Cancer |
|
| GOG-8808 |
Phase I Study of Intraperitoneal Taxol in Patients with Recurrent and/or Persistent Gynecologic Carcinoma |
PMID 7912515
|
| GOG-7892 |
Phase II Hormone Therapy with Tamoxifen for Advanced or Recurrent Endometrial Adenocarcinoma |
Terminated
|
| GOG-180 |
Phase II Study of Danazol in Patients with Advanced or Recurrent Endometrial Cancer |
PMID 12798713
|
| GOG-168 |
Phase II Study of Anastrozole (Arimidex) in Advanced, Recurrent or Persistent Endometrial Cancer |
PMID 10926805
|
| GOG-167 |
Prospective Study of Immediate Hysterectomy and Phase II Randomized Study of Medroxyprogesterone Acetate (Provera) Versus Medroxyprogesterone Acetate Suspension (Depo-Provera) Prior to Hysterectomy in Patients With Atypical Endometrial Hyperplasia |
PMID 16400639
|
| GOG-166 |
Phase II Study of High-Dose Intravenous Progesterone and Doxorubicin for Progressive Endometrial Carcinoma Resistant to Ongoing Doxorubicin Alone |
|
| GOG-159 |
Phase II Study of ZDX in Advanced, Recurrent, or Persistent Endometrial Cancer |
|
| GOG-153 |
Phase II Study of Alternating Courses of Megestrol and Tamoxifen for Recurrent or Persistent Endometrial Adenocarcinoma |
PMID 14751131
|
| GOG-147 |
Companion Protocol to Evaluate the Quality of Life in Patients with Advanced Endometrial Cancer Simultaneously Enrolled on GOG-122 |
|
| GOG-139 |
Phase III Randomized Study of DOX/CDDP Administered on Standard vs Circadian-Timed Schedules in Patients with Primary Stage III/IV/Recurrent Endometrial Carcinoma |
PMID 14551299
|
| GOG-129L |
Phase II Study of 6-Hydroxymethylacylfulvene (Irofulven) in Patients With Persistent or Recurrent, Refractory Endometrial Carcinoma |
PMID 15122083
|
| GOG-129J |
Phase II Study of Topotecan in Patients With Persistent, Recurrent, or Refractory Endometrial Carcinoma |
PMID 12468321
|
| GOG-129I |
Phase II Study of Pyrazoloacridine (PZA) in Patients with Recurrent or Refractory Endometrial Carcinoma |
PMID 11812081
|
| GOG-129H |
Phase II Study of the Effects of DOXIL in the Treatment of Recurrent or Persistent Endometrial Carcinoma |
PMID 11981008
|
| GOG-129E |
Phase II Study of Dactinomycin for Recurrent or Persistent Endometrial Carcinoma |
PMID 10600310
|
| GOG-129C |
Phase II Study of TAX for Recurrent or Persistent Endometrial Cancer |
PMID 12648575
|
| GOG-129B |
Phase II Study of Prolonged Oral VP-16 in Patients with Recurrent or Advanced Endometrial Cancer |
|
| GOG-122 |
Phase III Randomized Trial of Whole-Abdominal Irradiation vs DOX/CDDP in Patients Who Have Undergone Maximum Debulking of Advanced Endometrial Carcinoma |
PMID 16330675
|
| GOG-121 |
Phase II Trial of High-Dose MEG in Patients with Advanced or Recurrent Endometrial Carcinoma |
|
| GOG-119 |
Phase II Study of Tamoxifen plus Medroxyprogesterone for Advanced, Recurrent, or Metastatic Endometrial Carcinoma |
PMID 14751130
|
| GOG-107 |
Phase III Randomized Study Comparing ADR vs ADR/CACP in Patients with Recurrent Primary Stage III/IV Endometrial Carcinoma |
PMID 15459211
|
| GOG-99 |
Phase III Randomized Evaluation of Adjuvant Postoperative Pelvic Radiotherapy vs No Adjuvant Therapy for Surgical Stage I and Occult Stage II Intermediate-Risk Endometrial Carcinoma |
PMID 14984936
|
| GOG-96 |
Phase II Circadian-Timed Combination Chemotherapy with ADR/CDDP in Patients with Advanced Primary Endometrial Carcinoma |
PMID 8256764
|
| GOG-94 |
Phase II Study of Whole-Abdominal Radiotherapy in Patients with Papillary Serous Carcinoma and Clear Cell Carcinoma of the Endometrium or with Maximally Debulked Advanced Endometrial Carcinoma |
PMID 16213007
|
| GOG-860 |
Phase II Master Protocol for Chemotherapy in Patients with Advanced or Recurrent Carcinoma of the Endometrium --- TAX/G-CSF |
|
| GOG-86J |
Phase II Master Protocol for Treatment of Patients with Advanced or Recurrent Carcinoma of the Endometrium --- Tumor Necrosis Factor |
|
| GOG-86I |
Phase II Study of IFF/Mesna for Advanced or Recurrent Carcinoma of the Endometrium |
|
| GOG-86E |
Phase II Master Protocol for Chemotherapy in Patients with Advanced or Recurrent Carcinoma of the Endometrium --- Vincristine |
PMID 8424397
|
| GOG-86D |
Phase II Master Protocol for Chemotherapy in Patients with Advanced or Recurrent Carcinoma of the Endometrium --- MTX |
PMID 2407104
|
| GOG-86 |
Phase II Master Protocol for Advanced or Recurrent Carcinoma of the Endometrium: Phase I/II Study of Hexamethylmelamine |
PMID 3141250
|
| GOG-083 |
Phase II Clinico-Pathological Study of Adjuvant Chemotherapy with L-PAM in Patients with Simultaneous Endometrial and Ovarian Carcinoma |
|
| GOG-81F |
Master Protocol for Hormonal Treatment of Advanced or Recurrent Endometrial Carcinoma --- Phase II Tamoxifen for Disease Responsive to Progestins |
PMID 11208827
|
| GOG-81 |
Phase III Randomized Study of Low-Dose vs High-Dose Medroxyprogesterone Acetate (Provera) in Patients with Advanced, Persistent, or Recurrent Endometrial Carcinoma |
PMID 11208827
|
| GOG-62 |
Data Collection Form for Extravasation Injury with Doxorubicin |
|
| GOG-48 |
Phase III Provera (MPA) vs ADR vs ADR/CTX for Stage III/IV or Recurrent Endometrial Cancer |
PMID 8021731
|
| GOG-28 |
Phase III L-PAM/5-FU/MEG Chemotherapy vs ADR/CTX/5-FU/MEG for Primary Stage III or IV Recurrent or Residual Endometrial Cancer |
PMID 6371627
|
| GOG-34 |
Phase III Randomized Trial of Surgery plus Radiotherapy Followed by Chemotherapy with ADR vs Surgery plus Radiotherapy Alone in Patients with High-Risk Stage I/High-Risk Occult Stage II Endometrial Carcinoma, Including Those with Adnexal Metastases |
PMID 2298404
|
| GOG-30 |
Phase II Chemotherapy with Adriamycin for Endometrial Adenocarcinoma |
|
| GOG-26MM |
Phase II Master Protocol for Advanced, Recurrent Gynecologic Malignancies: EDAM |
PMID 7900709
|
| GOG-26KK |
Phase II Master Protocol for Advanced, Recurrent Endometrial Carcinoma: Merbarone |
PMID 8554040
|
| GOG-26HH |
Phase II Master Protocol for Advanced, Recurrent Pelvic Gynecologic Malignancies: Fluorouracil/Leucovorin |
|
| GOG-26GG |
Phase II Master Protocol for Advanced, Recurrent Pelvic Gynecologic Malignancies: Fazarabine |
PMID 7534978
|
| GOG-26Y |
Phase II Master Protocol for Advanced, Recurrent Gynecologic Malignancies: Vinblastine |
PMID 2239800
|
| GOG-26W |
Phase II Master Protocol for Advanced, Recurrent Gynecologic Malignancies: Echinomycin |
PMID 2198794
|
| GOG-26V |
Phase II Master Protocol for Advanced, Recurrent Gynecologic Malignancies: N-Methylformamide |
PMID 2384305
|
| GOG-26T |
Phase II Master Protocol Chemotherapy with 4'-Deoxydoxorubicin for Advanced, Recurrent Pelvic Malignancies |
PMID 2557300
|
| GOG-26P |
Phase II Master Protocol for Advanced, Recurrent Pelvic Malignancies: AT-125 |
PMID 3700040
|
| GOG-26M |
Phase II Chemotherapy with PALA for Advanced Recurrent Pelvic Malignancies |
PMID 6731346
|
| GOG-26K |
Phase II Chemotherapy with Chlorozotocin for Advanced, Recurrent and Metastatic Pelvic Malignancies in Progression |
|
| GOG-26J |
Phase II Chemotherapy with YOSHI-864 for Advanced, Recurrent Pelvic Malignancies |
PMID 6288239
|
| GOG-26H |
Phase II Chemotherapy with Maytansine for Advanced Recurrent Pelvic Malignancies |
PMID 6869315
|
| GOG-26I |
Phase II Chemotherapy with AMSA for Advanced, Recurrent Pelvic Malignancies (Cervix) |
PMID 6687445
|
| GOG-26G |
Phase II Master Protocol for Advanced, Recurrent Pelvic Malignancies: ICRF-159 |
PMID 3953488
|
| GOG-26F |
Phase II Chemotherapy with Baker's Antifol for Advanced Recurrent Pelvic Malignancies |
PMID 6236163
|
| GOG-26E |
Phase II Master Protocol for Advanced, Recurrent Gynecologic Malignancies: Dianhydrogalactitol |
PMID 6511240
|
| GOG-26D |
Phase II Master Protocol for Advanced, Recurrent Gynecologic Malignancies: VP-16 |
PMID 6509456
|
| GOG-26B |
Phase II Chemotherapy with Piperazinedione for Advanced Gynecologic Malignancies in Women |
PMID 3754086
|
| GOG-23 |
Chemotherapy with ADR/VCR/CTX for Carcinoma of the Cervix and for Adenocarcinoma of the Endometrium |
|
| GOG-18 |
Multimodality Therapy with Surgery and Radiotherapy for Stage II Adenocarcinoma and Adeno-Acanthoma of the Endometrium |
Terminated
|
| GOG-17 |
Radiotherapy plus Endocrine Therapy with Progestin for Stage III and Stage IV Adenocarcinoma of the Endometrium |
Terminated
|
| GOG-16 |
Preoperative vs Postoperative Radiotherapy Adjunctive to Surgery for Stage I Adenocarcinoma of the Endometrium |
Terminated
|
| GOG-15 |
Modified Phase II-III Chemotherapy with CCNU or MeCCNU for Advanced Gynecologic Cancers |
PMID 350400
|
| GOG-P12 |
Relation of Progestin Receptor Concentration to Efficacy of Progestin Therapy for Endometrial Adenocarcinoma - Pilot Study |
|
